XOMA ROYALTY CORPORATION (XOMA) Stock Price, Quote, News and Overview
NASDAQ:XOMA - Nasdaq - US98419J2069 - Common Stock - Currency: USD
XOMA Quote, Performance and Key Statistics
XOMA ROYALTY CORPORATION
NASDAQ:XOMA (1/24/2025, 4:30:02 PM)
26.7
+0.69 (+2.65%)
The current stock price of XOMA is 26.7 USD. In the past month the price increased by 0.3%. In the past year, price increased by 32.24%.
XOMA Latest News, Press Releases and Analysis
Bullish Two Hundred Day Moving Average Cross - XOMA
XOMA Royalty's Series A Preferred Stock Crosses Above 8.5% Yield Territory
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty January 2025 Dividend Record and Payment Dates...
XOMA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About XOMA
Company Profile
XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
Company Info
XOMA ROYALTY CORPORATION
2200 Powell Street, Suite 310
Emeryville CALIFORNIA 94608 US
CEO: James Neal
Employees: 13
Company Website: https://www.xoma.com/
Investor Relations: http://investors.xoma.com/
Phone: 15102047239
XOMA FAQ
What is the stock price of XOMA?
The current stock price of XOMA is 26.7 USD.
What is the symbol for XOMA ROYALTY CORPORATION stock?
The exchange symbol of XOMA ROYALTY CORPORATION is XOMA and it is listed on the Nasdaq exchange.
On which exchange is XOMA stock listed?
XOMA stock is listed on the Nasdaq exchange.
Is XOMA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for XOMA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of XOMA.
Does XOMA stock pay dividends?
XOMA does not pay a dividend.
What is the Price/Earnings (PE) ratio of XOMA?
XOMA does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.1).
What is the Short Interest ratio of XOMA stock?
The outstanding short interest for XOMA is 1.29% of its float.
XOMA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to XOMA. When comparing the yearly performance of all stocks, XOMA is one of the better performing stocks in the market, outperforming 70.15% of all stocks.
XOMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XOMA. XOMA has a bad profitability rating. Also its financial health evaluation is rather negative.
XOMA Financial Highlights
Over the last trailing twelve months XOMA reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 8.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.99% | ||
| ROE | -50% | ||
| Debt/Equity | 1.27 |
XOMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to XOMA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 46.73% and a revenue growth 338.82% for XOMA